Formosa Pharmaceuticals, Inc. (TWSE: 6838), a Taiwan-based biopharmaceutical company, announced on Friday that it has submitted a Clinical Trial Application (CTA) to European regulatory authorities to conduct a pivotal clinical trial of TSY-110.
The product is a biosimilar candidate referencing Roche's antibody-drug conjugate Kadcyla (ado-trastuzumab emtansine), indicated for HER2-positive metastatic and early-stage breast cancer.
The upcoming trial is designed subsequent to regulatory guidance from both US and EU authorities, and will assess the safety, tolerability, pharmacokinetics, and immunogenicity profile of TSY-110 compared with the reference product.
Senhwa completes enrolment in Phase 1b expansion trial of CX-5461
McKesson to acquire Precision Medicine Group for approximately USD2.25bn
Astellas doses first patient in Phase 3 study of ASP2138
Gilead expands Trodelvy role in first-line metastatic triple-negative breast cancer in Europe
GSK's Jemperli wins FDA priority review for advanced rectal cancer
Leads Biolabs NDA for Opamtistomig accepted by China's CDE
Ipsen completes Kartos Therapeutics acquisition, strengthening late-stage oncology pipeline
Nuvation Bio's safusidenib granted FDA Fast Track Designation for IDH1-mutant glioma treatment